Lexaria Bioscience (LEXX) Liabilities from Discontinued Operations (2014 - 2020)
Lexaria Bioscience's (LEXX) quarterly Liabilities from Discontinued Operations came in at 250.0 in Q3 2020, little changed quarter-over-quarter from 250.0 in Q2 2020.
Lexaria Bioscience (LEXX) Liabilities from Discontinued Operations (2014 - 2020) Analysis & Trends
Lexaria Bioscience has disclosed Liabilities from Discontinued Operations across 2 years of filings, most recently posting 250.0 for Q3 2020.
- Liabilities from Discontinued Operations for Q3 2020 came in at 250.0, changed N/A year-over-year; the trailing twelve-month figure through Aug 2020 was 250.0 (changed N/A YoY), and the FY2020 annual result was 250.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations came in at 250.0 for Q3 2020 at Lexaria Bioscience, roughly flat from 250.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 250.0 in Q2 2020 to a low of 250.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2020 | 250.00 |
| Aug 31, 2020 | 250.00 |
| May 31, 2020 | 250.00 |
| May 31, 2020 | 250.00 |
| Nov 30, 2014 | 678,193.00 |
| Nov 30, 2014 | 678,193.00 |